In the PI3K/AKT pathway, options include Capivasertib (used in metastatic breast cancer with PIK3CA/AKT1/PTEN alterations [38]), RLY-2608 (PIK3CA inhibitor [39]), and PI3Kβ inhibitors like GSK2636771 and AZD8186 [40,41]. This evidence concerns the gene PIK3CA and breast carcinoma.